Quantcast

Latest Paclitaxel Stories

2014-07-24 12:27:55

BUFFALO, N.Y., July 24, 2014 /PRNewswire/ -- Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months. KX2-391 is a synthetic, orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization. KX2-391 promotes the induction of p53, G2/M arrest...

2014-07-23 16:28:13

Innovative Technology Adds To Company's Leading Portfolio of Treatment Options for Coronary Artery Disease MARLBOROUGH, Mass., July 23, 2014 /PRNewswire/ -- Continuing to advance the development of innovative treatment options for coronary artery disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark and begun the European market launch of the Agent(TM) Paclitaxel-Coated PTCA Balloon Catheter. The Agent Drug-Coated Balloon (DCB) provides physicians with an...

2014-07-22 08:32:36

Additional Independent Review Board Approvals Expected for Phase 2 Trial (Study 202) SAN DIEGO, July 22, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant...

2014-07-15 08:28:12

HARBIN, China, July 15, 2014 /PRNewswire/ -- Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today announced the appointment of Tong Liu and Hengjiang (Henry) Pang to the Company's Board of Directors, effective August 1, 2014. "Tong and Henry are both excellent additions to our Board, with strong cross...

2014-07-14 08:27:37

Innovative Technology Strengthens Company's Leading Portfolio of Solutions for Peripheral Vascular Disease MARLBOROUGH, Mass., July 14, 2014 /PRNewswire/ -- Demonstrating its continued leadership in the development of innovative solutions for peripheral vascular disease, Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Ranger(TM) Paclitaxel-Coated PTA Balloon Catheter. The technology is now in full European market launch. The Ranger Drug-Coated Balloon (DCB)...

2014-07-08 08:29:42

CALGARY, July 8, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN(®) versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). The principal investigator is Tanios Bekaii-Saab, MD, associate professor and gastrointestinal oncology section...

2014-06-30 12:31:55

BUFFALO, N.Y. and SEOUL, South Korea, June 30, 2014 /PRNewswire/ -- Hanmi Pharmaceuticals announces a positive study on Oraxol® use in a Phase I/II clinical proof-of-concept study (Study HM-OXL-201) of Oraxol - an oral form of the approved drug paclitaxel, with HM30181, a highly potent and selective, P-glycoprotein inhibitor of the gastro-intestinal tract. The study, entitled "A phase I-II clinical trial to determine the recommended dose and to assess the efficacy, safety and...

2014-06-25 08:32:07

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Concortis Biosystems, Inc. (Concortis), a subsidiary of Sorrento Therapeutics (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced a collaboration to generate novel antibody drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutic agents using Concortis' proprietary ADC Technology. Under the terms of the agreement, Sorrento will receive...

2014-06-20 16:22:56

SAN DIEGO, June 20, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced that Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento, will present at the BIO Business Forum, taking place June 23(rd)-26(th), 2014 in San Diego, CA. The presentation will take place in the Imperial Beach Presentation Room on Tuesday, June 24 at 2:45 pm...

2014-06-12 23:00:57

Health Canada has reinstated Biolyse Pharma’s Establishment Licence (EL) after sending in a team of inspectors to look at manufacturing within the St.Catharines based Pharmaceutical. The new team of inspectors found Biolyse to be in compliance with Canadian Good Manufacturing Practices (GMP) and assigned the company a "C" (conformance) rating. St.Catharines, Ontario (PRWEB) June 12, 2014 The Establishment Licensing Unit of Health Canada announced today that as a result of a...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related